Hamburg - Delayed Quote EUR
Dermapharm Holding SE (DMP.HM)
37.40
-0.10
(-0.27%)
As of 8:16:08 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,180,766
1,180,766
1,135,351
1,024,776
942,912
Cost of Revenue
413,696
413,696
416,191
363,943
322,218
Gross Profit
767,070
767,070
719,160
660,833
620,694
Operating Expense
552,338
552,338
539,059
418,784
333,651
Operating Income
214,732
214,732
180,101
242,049
287,043
Net Non Operating Interest Income Expense
-46,448
-46,448
-69,734
-13,846
-5,814
Pretax Income
172,005
172,005
105,997
216,297
292,977
Tax Provision
60,268
60,268
45,462
83,680
84,073
Net Income Common Stockholders
113,787
113,787
62,368
134,236
209,583
Diluted NI Available to Com Stockholders
113,787
113,787
62,368
134,236
209,583
Basic EPS
2.11
--
1.16
2.49
3.89
Diluted EPS
2.11
--
1.16
2.49
3.89
Basic Average Shares
53,840
--
53,840
53,840
53,840
Diluted Average Shares
53,840
--
53,840
53,840
53,840
Total Operating Income as Reported
216,933
216,933
182,894
243,687
298,469
Rent Expense Supplemental
7,628
7,628
6,534
6,422
4,882
Total Expenses
966,034
966,034
955,250
782,727
655,869
Net Income from Continuing & Discontinued Operation
113,787
113,787
62,368
134,236
209,583
Normalized Income
113,267.96
113,267.96
58,330.50
133,459.82
203,058.34
Interest Income
13,988
13,988
2,494
325
4,022
Interest Expense
58,408
58,408
54,968
12,338
8,837
Net Interest Income
-46,448
-46,448
-69,734
-13,846
-5,814
EBIT
230,413
230,413
160,965
228,635
301,814
EBITDA
320,908
320,908
265,552
329,815
357,410
Reconciled Cost of Revenue
413,696
413,696
416,191
363,943
322,218
Reconciled Depreciation
86,785
86,785
101,772
94,909
55,159
Net Income from Continuing Operation Net Minority Interest
113,787
113,787
62,368
134,236
209,583
Total Unusual Items Excluding Goodwill
799
799
4,750
1,266
9,151
Total Unusual Items
799
799
4,750
1,266
9,151
Normalized EBITDA
320,109
320,109
260,802
328,549
348,259
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
279.96
279.96
712.50
489.82
2,626.34
12/31/2021 - 7/2/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade